NZ623573B2 - 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d] pyrimidine derivatives, manufacture and their use as antiviral active substances - Google Patents

Abstract

The disclosure relates to 5-amino-3-pheylamino-6-phenylpyrazolo[3,4-d] pyrimidine derivatives of the general formula (I) or pharmaceutically acceptable salts or prodrugs thereof, wherein at least one hydrogen atom is replaced in at least one of phenyl groups A and B by a substituent RH, which has a Hammett constant ? greater than 0.23. The disclosure further relates to a method of manufacturing these. Corresponding compounds have been found to have surprisingly high activity against viruses, particularly rhinoviruses and picornaviruses. Moreover, the compounds are very well tolerated. For these reasons, the compounds are suited for the treatment of viral infections and as medications. Hammett constant ? greater than 0.23. The disclosure further relates to a method of manufacturing these. Corresponding compounds have been found to have surprisingly high activity against viruses, particularly rhinoviruses and picornaviruses. Moreover, the compounds are very well tolerated. For these reasons, the compounds are suited for the treatment of viral infections and as medications.

Description

-AMINOPHENYLAMINOPHENYLPYRAZOLO[3,4-D] DINE DERIVATIVES, MANUFACTURE AND THEIR USE AS ANTIVIRAL ACTIVE SUBSTANCES Description The invention generally concerns new types of 4-aminophenylaminophenylpyrazolo[3,4- d]pyrimidine derivatives and their use as antiviral agents, preferably for the treatment of picornavirus infections.

Picornaviruses, especially enteroviruses and rhinoviruses, are sible for a broad spectrum of es in humans. The enteroviruses include more than 60 different human pathogenic serotypes (Melnick J in: Fields B et al., editors. Virology. Philadelphia: Lippincott-Raven hers; 1996, 655-712). Enterovirus, echovirus, coxsackievirus A and B infections often take a course of nonspecific fever and cause diseases of the upper respiratory tract which frequently cannot be distinguished from rhinovirus infections. More serious clinical pictures which can also occur as epidemics, include hagic conjunctivitis, herpangina, hand-foot-and-mouth disease, aseptic meningitis, encephalitis and acute myocarditis. Thus different virus types can cause the same symptoms or one virus type can cause quite different clinical pictures. With the introduction of modern and sensitive methods in virus diagnostics persistent enteroviral RNA as well as virus proteins could be identified in connection with chronic diseases such as type 2 diabetes, poliomyositis and especially chronic myocarditis. Persistent enterovirus infections also occur in patients with globulinemia and present as persistent enterovirus meningoencephalitis. Dermatomyositis or polymyositis often ed as attendant symptoms. The rhinoviruses e approx. 100 serotypes. irus infections cause more than half of all respiratory diseases of the upper respiratory tract in humans (Couch RB in: Fields BM et al., editors: Fields Virology, 3rd edition. cott-Raven, Philadelphia, 1996, 713-35). In an average duration of the disease of approx. 10 days these colds which take a mostly harmless course lead to millions of GP visits and time off school and work each year. Possible complications e otitis media, sinusitis, exacerbation of asthma and cystic fibrosis as well as infections of the lower respiratory tract especially in young children, older patients and -suppressed patients. Because of the variety of types prophylactic vaccination is currently not possible. As a result of the working days lost, GP visits and medicines associated with these illnesses rhinoviruses and enteroviruses mean significant costs ly. The ent of these viral infections to date has depended on symptoms as there are no specific therapeutic agents available (Rotbart HA: Antiviral Res 2002, 53(2), 83-98). In addition, antibiotics are often prescribed ssarily. The development of new virustatic agents is therefore absolutely essential.

The results of the intensive search for ial treatments for enterovirus and irus infections were summarised by Rotbart in 2002 in an overview e (Rotbart HA: Antiviral Res 2002, 53(2), . For example, ribavirin inhibits a host cell enzyme, the inosine 5’-monophosphate (IMP) ogenase. By deactivating this key enzyme for the synthesis of purine tides, the replication of picornaviruses is inhibited in vitro and in vivo. Furthermore, ribavirin is to be inserted directly into the genome of polio viruses and thereby also act as a mutagen for RNA viruses (Crotty S et al.: Nat Med, 2000, 6(12),1375-9). Because of serious side s these compounds are not used to treat rhinovirus and enterovirus infections. Specific targets to prevent viral RNA synthesis are the genome itself, the viral RNA-dependent RNA polymerase as well as other viral proteins necessary for the replication complex. ines, thiosemicarbazones, benzimidazoles , dipyridamoles and flavones have been known for a long time as inhibitors of the polymerases of different picornaviruses in the cell culture. Varying degrees of success were thereby ed in vivo. Enviroxime derivatives are deemed to be the most promising candidate with broad nterovirus and anti-rhinovirus activity. Enviroxime impedes the synthesis of plus strand RNA by binding to the virus protein 3A, which is necessary for the formation of RNA intermediates in virus reproduction (Heinz BA and Vance LM: J Virol, 1995, 69(7), 4189-97). In clinical s moderate or no therapeutic effects, poor pharmacokinetics and undesirable side effects were observed (Miller FD et al.: Antimicrob Agents Chemother, 1985, 27(1), 102-6). To date there is no clinical data available for newer derivatives with better bioavailability and tolerance.

Based on the knowledge of the fine structure and on of the viral protease 2C the protease inhibitor AG 7088 was developed. AG 7088 acts in the cell culture in the nanomolar concentration range against 48 rhinovirus types as well as coxsackie virus A21, B3, enterovirus 70 and rus 11 (Pattick AK et al.: Antimicrobila Agents Chemother, 1999, 43(10), 2444-50). The ding data of the clinical studies are not known to date.

With the clarification of the molecular ure of the viral capsids the prerequisites for a targeted design of capsid blockers, the "WIN substances" were created (Diana GD: Curr Med Chem 2003, 2, 1-12). They hinder the adsorption and/or the uncoating of rhinoviruses and viruses.

Some of the WIN substances only act extremely specifically against individual genus types or virus types of the picornaviruses. Other derivatives inhibit the replication of rhinoviruses as well as enteroviruses. The WIN substances e for example arildone, disoxaril and pirodavir.

These compounds showed very good antiviral effects in the cell culture. Poor solubility (arildone), low ilability (arildone and disoxaril), fast metabolisation and excretion (disoxaril and WIN 54954) as well as side effects, for example skin rash (WIN 54954), made a clinical application impossible. Great hopes were placed on pleconaril, another capsid inhibitor. Pleconaril has a very good oral bioavailability and after binding to the hydrophobic pocket in the virus capsid inhibits the penetration of rhinoviruses, echoviruses and coxsackie viruses (Pevear DC et al.: Antimicrob Agents Chemother 1999, 43(9), 2109-15; McKinlay MA et al.: Annu Rev Microbiol 1992, 46, 635- 54). Therefore it is ially effective against a broad um of viral diseases, from the common cold h to viral meningitis or myocarditis. ance was observed in the case of rhinoviruses , enterovirus 71 and kie virus B3 (Ledford RM et al.: J Virol 2004, 78(7), 3663-74; Groarke JM et al.: J Infect Dis 1999, 179(6), 1538-41). Clinical s of children and adults with enterovirus meningitis (Abzug MJ et al.: Pediatr Infect Dis J, 2003, 22, 335-41) as well as respiratory infections caused by the rhinovirus (Hayden FG et al.: Antivir Ther, 2002, 7, 53-65; Hayden FG et al.: Clin Infect Dis, 2003, 36, 1523-32) went well. The proven eutic effect however is not sufficient for licensing pleconaril (Picovir, Viropharma, USA) to treat rhinovirus infections in the USA. In March 2002 a corresponding application was refused by the Food and Drug Administration : FDA on the grounds of an unfavourable risk-benefit assessment.

Pyrazolopyrimidines have also been bed as CRF antagonists (Corticotropin-Releasing Factor Antagonists) (e.g. EP 674 642 and EP 691 128), which, for e, inhibit adenosine kinase (EP 496 617 or US 4,904,666), xanthine oxigenase (J. Heterocyc. Chem. 19, 1565, 1982) or other enzyme systems (US 2,965,643 and US 3,600,389).

Thus it continues to be a crucial part of antiviral research to p highly effective antiviral agents to treat rhinovirus and enterovirus diseases. The new compounds should be well tolerated and overcome existing resistance, e.g. in the case of pleconaril.

WO 00/43394 A discloses substituted pyrazolo[3,4-d]pyrimidine derivatives and their use as antiviral agents.

EP 2 049 540 also discloses 4-aminoarylaminoarylpyrazolo[3,4-d]pyrimidine derivatives and their use as antiviral agents.

The purpose of the invention is to specify other pyrazolo[3,4-d]pyrimidine tives as well as their manufacture and use which can be used as antiviral agents against enteroviruses and rhinoviruses as well as avoid the stated antages of the prior art, for example, with regard to the stability and bioavailability of the substances; and/or to provide the public with a useful choice.

Accordingly, the first aspect the invention provides 4-aminophenylaminophenylpyrazolo[3,4- d]pyrimidine derivatives of the general formula I NH NH2 N N H B or a pharmaceutically acceptable salt or pro-drug thereof, n the pro-drug has a imino(phenyl)methyl substituent on the pyrazol heteroatom in position 1, wherein at least one hydrogen atom in at least one of the phenyl groups A and B is substituted by a substituent RH which has a Hammett constant σp greater than 0.23, wherein each further en atom in each of the phenyl groups A and B can be substituted independently of each other by a residue R1, wherein each R1 ndently can be a halogen, a ted or unsaturated, linear or branched aliphatic radical with 1-7 chain members, a saturated or unsaturated, linear or branched alcanol radical with 1-8 chain members, NO2, CN, CONR22, COR2, COOR2, OR2, SR2, NR22, SO2NR22, CX3, CR2X2, OCX3, OCR2X2, or phenyl; each R2 independently is hydrogen, a saturated or unsaturated, halogenated or non-halogenated, linear or ed aliphatic radical with 1-7 chain members, benzyl, phenyl or naphtyl, a saturated or unsaturated, mono- or polyheterocycle with the heteroatoms N, S or O, wherein each of the groups mentioned above independently can be substituted with fluorine, chlorine, e, trifluormethyl , alkyl, , cyano, nitro, amino, aminoalkyl, C(O)-alkyl, C(O)O-alkyl, benzyl, phenyl or naphtyl; and X independently is F, Cl, Br, or I.

In another aspect, the invention provides a pharmaceutical composition, comprising a 4-amino phenylaminophenylpyrazolo[3,4-d]pyrimidine derivative according to the invention.

In another aspect, the invention provides a method of manufacturing a pharmaceutical composition , comprising ating a 4-aminophenylaminophenylpyrazolo[3,4-d]pyrimidine tive according to the invention with a pharmaceutically acceptable carrier.

In r aspect, the invention relates to the use of a 4-aminophenylamino phenylpyrazolo[3,4-d]pyrimidine derivative according to the invention in the manufacture of a medicament.

In r aspect, the invention reltes to the use of a 4-aminophenylamino phenylpyrazolo[3,4-d]pyrimidine derivative according to the invention in the manufacture of a medicament for the prophylactic or therapeutic treatment of a viral infection.

In another aspect, the invention es a method of manufacturing a 4-aminophenylamino pyrazolo[3,4-d]pyrimidine derivative according to the invention or according to the formula I in the first aspect of the invention, wherein each hydrogen atom in each of the phenyl groups A and B independently of each other can be tuted by a residue R1, as defined in the first aspect of the invention, comprising the conversion of a 5-aminocyanophenylaminopyrazol with the free base of a benzamidine in a polar organic solvent.

Certain statements that appear below are broader than what appears in the statements of the invention above. These statements are provided in the interests of providing the reader with a better tanding of the invention and its practice. The reader is directed to the accompanying claim set which s the scope of the invention.

Also described are substituted 4-aminophenylaminophenylpyrazolo[3,4-d]pyrimidine derivatives of the general formula I, including their ceutically tolerated salt compounds and their pro-pharmacons, NH NH2 N N H B wherein at least one hydrogen atom in at least one of the phenyl groups A and B is replaced by a substituent RH, which has a Hammett nt σp greater than 0.23, wherein every further hydrogen atom in each of the phenyl groups A and B can be replaced independently of each other by a residue R1 , wherein each R1 independently can be a n, a saturated or unsaturated, linear or branched aliphatic radical with 1-7 chain members, a saturated or unsaturated, linear or ed alcanol radical with 1-8 chain members, NO2, CN, CONR22, COR2, COOR2, OR2, SR2, NR22, SO2NR22, CX3, CR2X2, OCX3, OCR2X2, or phenyl; each R2 independently is hydrogen, a saturated or unsaturated, halogenated or non- halogenated , linear or branched aliphatic radical with 1-7 chain members, benzyl, phenyl or naphtyl , a saturated or rated, mono- or polyheterocycle with the heteroatoms N, S or O, wherein each of the above-mentioned groups can be independently substituted with fluorine, chlorine, bromine, ormethyl, alkyl, alkoxy, cyano, nitro, amino, aminoalkyl, C(O)-alkyl, C(O)O-alkyl, benzyl, phenyl or naphtyl; and X independently is F, Cl, Br, or I. ically substituted 4-aminophenylaminophenylpyrazolo[3,4-d]pyrimidine derivatives are also described, as the potential applications, without limiting the invention in any way. ophenylaminophenylpyrazolo[3,4-d]pyrimidine derivatives of the general formula I are advantageous, n at least one hydrogen atom in at least one of the phenyl groups A and B is replaced by a substituent RH, selected from NO2, CN, CF3, CCl3, CBr3, OCF3, OCCl3, OCBr3, CHF2, CHCl2, CHBr2, , CHO, COOH, COMe, COEt, COOMe or COOEt, preferably CF3 or OCF3. It is an advantage that in one or both phenyl groups A and B one, two or three hydrogen atoms are replaced by a substituent RH. In a special embodiment precisely one hydrogen atom in one of the phenyl groups A and B is replaced by a substituent RH. The substituent RH can be in para position of the phenyl ring A or B.

In addition to RH each of the phenyl groups A and B can independently of each other carry further es R1. It is an advantage that the phenyl groups A and B independently of each other carry none, one, two or three further residues R1, preferring none or a further residue R1.

As alkyls it is worth considering in in particular linear or branched C1alkyls, for example, , ethyl, n-propyl, i-propyl and butyl. The same applies to alcanols, alkylamines and alkylamides.

Covered by the invention are in particular 4-aminophenylaminophenylpyrazolo[3,4- d]pyrimidine derivatives of the general formula II NH NH2 N N H B n each substituent RA, RB independently can be hydrogen, a halogen, a saturated or unsaturated , linear or branched aliphatic radical with 1-7 chain members, a saturated or unsaturated , linear or branched alcanol radical with 1-8 chain s, NO2, CN, CONR22, COR2, COOR2, OR2, SR2, NR22, 2, CX3, CR2X2, OCX3, OCR2X2, or phenyl; and R2 and X as defined above; wherein at least one of the substituents RA, RB has a Hammett constant σp greater than 0.23.

The invention includes in particular 4-aminophenylaminophenylpyrazolo[3,4-d]pyrimidine derivatives of the general formula IIa NH NH2 N N IIa, or IIb NH NH2 N N R IIb, wherein RH is selected from NO2, CN, CF3, CCl3, CBr3, OCF3, OCCl3, OCBr3, CHF2, CHCl2, CHBr2, , CHO, COOH, COMe, COEt, COOMe or COOEt, preferably CF3 or OCF3.

Also included are pharmaceutical compositions, which contain a 4-Aminophenylamino phenylpyrazolo[3,4-d]pyrimidine derivative ing to the general formulas I, II, IIa or IIb. Such pharmaceutical compositions can contain further substances, for example, pharmaceutically acceptable excipients and carriers. In a particular aspect the ceutical compositions can include additional active ingredients, in particular antiviral agents, especially active agents against picornaviruses.

Surprisingly, it was shown that the 4-aminophenylaminophenylpyrazolo[3,4-d]pyrimidine derivatives in the ion have a significantly better stability in liver microsomes compared with the state-of-the-art substances. Furthermore investigations on the pharmacokinetics in mice showed that the 4-aminophenylaminophenylpyrazolo[3,4-d]pyrimidine derivatives in the invention have a significantly better bioavailability than state-of-the-art nces. At the same time the compounds of the present invention show strong antiviral activity against picornaviruses, especially enteroviruses and rhinoviruses in the nano or olar concentration range.

Therefore the pharmaceutical preparations which contain a compound of the formulas I, II, IIa or IIb, are particularly suitable for the treatment of atory infections, aseptic meningitis, encephalitis , herpangina etc. in humans and animals, which can be caused by aviruses especially enteroviruses and rhinoviruses.

The 4-aminophenylaminophenylpyrazolo[3,4-d]pyrimidine derivatives are characterised by the fact that they carry at least one substituent RH on one or on both phenyl groups, which has a Hammett constant σp greater than 0.23. This value 0.23 corresponds to the Hammett constant σp of the bromine, which shows the highest Hammett constant for the para position among the halogens.

The ination of the Hammett constants for ent tuents is based on the ionization constants of the benzoic acid according to the Hammett equation σx = log KX – log KH wherein KH is the ionization constant for benzoic acid in water at 25 °C and KX is the ponding constant for a meta or para substituted benzoic acid. A method to determine the Hammett constant for different substituents in meta (σm) and para position ( σp) as well as values already ascertained of a variety of substituents can be taken from the publication of Hansch et al., "A Survey of t Substituent Constants and Resonance and Field Parameters", in Chem. Rev. 1991. 97, 5, which is incorporated herein in its entirety. Of significance to this invention is thus exclusively the value σ respectively for the para position (σp), irrespective of the position where at least one substituent RH is finally located.

Examples of the invention are compounds in Table 1, including their pharmaceutically ted salt compounds.

Com- Formula t for Melting Molecu- MS EI Analysis 1H NMR pound crystallisation point oC lar formu- (m / z) Calculated (B) % (DMSO-d6) la (M+) Found (G) % d, ppm CRCV- F THF, Toluene - C18H13F3 370.3312 B: C 58.3; H - 340 NH NH2 N6 3.54; N 22.69 N N MS-112 NH NH2 EtOH - C18H13F3 386.3306 B: C 55.96; H - N6O 3.39; N 21.75 N N F F MS-115 Cl N NH 2 DMF/EtOH 272-74 C19H11Cl 472.7831 B: C 48.27; H - N F6N6 2.35; N 17.78 N CF N 3 G: C 48.31; H 2.50; N 17.64 H 13.10 (1Н, br.s., NH), MS-116 Cl N NH 2 Activated 271-73 C18H12Cl 404.7847 B: C 53.41; H 8.84 (1H, d, CH), N CF carbon, F3N6 2.99; N 20.76 8.55 (1H, br.s., NH), N 3 EtOH G: C 53.49; H 7.01-8.02 (9H, br.m, NH2, N N H 3.14; N 20.61 7CH) MS-117 N NH 2 EtOH 230-32 F3 370.3397 B: C 58.38; H - N N6 3.54; N 22.69 N G: C 58.61; H N CF N 3 H 3.67; N 22.45 Table 1 Also covered are pro pharmacons (prodrugs) of the compounds, especially those which are characterised by a substituent on the pyrazol heteroatom in position 1. It has been shown that such types of compounds are converted in vivo to the 1H pyrazol compound. As an example, compounds have been mentioned in t of which the pyrazol heteroatom in position 1 is substituted by an imino(phenyl)methyl substituent, such as, for example, 1-[Imino(phenyl)methyl] amino(4-trifluormethyl-phenyl)aminophenylpyrazolo[3,4-d]pyrimidine, also designated by the IUPAC name 1-benzylcarboximidoylphenylN-[4-(trifluormethyl)phenyl]-1H-pyrazolo[3,4-d]- pyrimidine-3,4-diamine. Here this relates to a by-product of the manufacture of the compound bed above, CRCV-340, resulting from the reaction of the compound CRCV-340 with an excess of idine in the reaction mixture and having the following formula: F NH N N 40-Prodrug It was found that these compounds (e.g. CRCV-340 prodrug) in vivo are very easily converted into the target nd in such a way that in the serum only the final active ingredient (e.g.

CRCV-340) can mainly be proven. Also included are the salts, solvates or solvates of the salts produced by the above compounds. Within the scope of this invention the preferred salts are physiologically harmless salts of the compounds relating to the invention. logically harmless salts of the compound relating to the invention include addition salts of mineral acids, carboxylic acids and sulphonic acids, e.g. salts from hydrochloric acid, hydrobromic acid, sulphuric acid, phosphaic acid, methane sulphonic acid, nic acetic acid, toluene sulphonic acid, benzenesulphonic acid, naphthalene-sulphonic acid, acetic acid, trifluoroacetic acid, propionic acid, lactic acid, tartaric acid, malic acid, citric acid, fumaric acid, maleic acid and c acid.

The invention shall be explained below in more detail using synthesising methods, special 4- aminophenylaminophenylpyrazolo[3,4-d]pyrimidine derivatives of the general formula (I) as well as their effect and use against picornavirus infections.

Fig. 1 shows a l diagram on the sis of pyrazolo[3,4-d]pyrimidine 1 and includes in the first step the condensation of [bis(methylthio)methylen]malononitril 2 with phenylamines 3 in alcohol to phenyl derivatives 4. The latter can be isolated respectively and purified for further ons or used directly without purification for subsequent reactions ("one-pot" reaction). The subsequent step constitutes the interaction of the phenyl derivative 4 with hydrazine or hydrazine derivatives. The on takes place by boiling for 1 to 4 hours and leads to a high yield of pyrazol . The final step of the synthesis of pyrazolo [3,4-d]pyrimidine 1 is the condensation of the pyrazol 5 with amidine 6 in the presence of acetic acid, trifluoroacetic acid or sodium acetate.

CN CN H2N 3 CN CN SMe SMe AlkOH SMe NH 2 4 CN HHal B 6 NH H2N R H2NNH2 A NH2 MeCOONa / AlkOH N N MeCOOH oder CF3COOH H A NH2 R NH 1 N Abb. 1 N H B The compounds can be thereby obtained ageously by transforming the pyrazol (5) in the last synthesis step with corresponding benzamidine hydrochloride in the presence of an excess of sodium acetate at 200-220 °C in the absence of solvents.

Alternatively the compounds can be obtained by converting the pyrazol (5) in the last synthesis step with corresponding benzonitrile (a large surplus) with microwave irradiation and in the presence of potassium-tert-butylate.

An alternative synthesis method is the "one-pot" reaction of malononitrile with aryl isothiocyanates in the presence of sodium hydride and a subsequent ent of the reaction mixture with methyl iodide or dimethyl te. In the process large amounts of enamine are produced. Here too the condensation of pyrazol 5 with arylamidines 6 in the presence of acid, such as acetic acid or trifluoroacetic acid, or their salts (acetate) is again the final synthesis step to produce pyrazolo ]pyrimidine 1.

It has been shown that the conversion of the pyrazol (5) to pyrazolo[3,4-d]pyrimidine with particularly high yields can be done by using the benzamidine components as a free base and the reaction is carried out in polar solvents. An advantage of this method is also that the proportion of byproducts which are difficult to separate can be minimised. This reaction can be effected, based on substituted 5-aminocyanophenylamino-pyrazoles (5) with optional substituted benzamidines as a free base (6) to 4-amino(phenylamino)phenylpyrazolo[3,4-d]pyrimidine (1) according to the following reaction diagram.

Fig. 2 The residues RA and RB are substituents, as d above for R1.

Whilst the conversion described above is particularly suitable for the manufacture of 4-amino phenylaminophenylpyrazolo[3,4-d]pyrimidine derivatives of the above general formula (I), wherein at least one hydrogen atom in at least one of the phenyl groups A and B is replaced by a tuent RH, which has a Hammett constant σp > 0.23, the method can also [be used?1] for the manufacture of 4-aminophenylaminophenylpyrazolo[3,4-d]pyrimidines, which have no such substituents, i.e. in which this residue represents hydrogen or a residue R1, as defined above in connection with formula I.

Also described are reactions, as described above, in which the residues RA and RB independently of each other can be selected from NO2, CN, CONR32, COOR3, CHO, CHONH2, a n, an rated or ted linear or ed aliphatic radical (called alkyl group) with 1 to 6 chain members, a saturated or unsaturated linear or branched alcanol radical (also called alcoxy group) 1 Translator's note: The verb is missing in the original ; "be used" is appropriate in this context. with 1 to 6 chain members, OR3, SR3, NR32, SO2NR3, di- or trifluormethyl and the e R3 can consist of H, methyl-, ethyl-, propyl- or butyl- groups. Insofar as the compounds of the invention can exist in tautomeric forms, the present invention ses all tautomeric forms.

The substituents in the aph above have the following meaning insofar as nothing is specified to the contrary: Alkyl as well as the alkyl parts in alkoxy stand for straight-chain or branched alkyls and comprise, if nothing to the contrary is , (C1-C6)-alkyl, especially (C1-C4)-alkyl, e.g. methyl, ethyl, propyl , isopropyl, butyl, isobutyl. Advantageously alkoxy stands for a straight-chain or branched alkoxy residue, especially with 1 to 6, in particular preferably 1 to 4 and mostly preferably 1 to 3 carbon atoms. As an e and as a preference methoxy, ethoxy, N-propoxy, isopropoxy, tbutoxy , n-pentoxy and n-hexoxy are ned. Aryl stands for a mono- to tricyclic aromatic, carbocyclic residue generally with 6 to 14 carbon atoms. As an example and as a preference aryl is selected from phenyl, naphthyl and phenantrenyl, in particular phenyl is preferred. Halogen stands for fluorine, chlorine, bromine and iodine, preferably ne and chlorine.

It is also possible with this method to manufacture general arylpyrazolo[3,4d]pyrimidine tives , wherein in this case the phenylamidine 6 is to be replaced by a corresponding arylamidine.

In particular instead of phenyl rings A and B also naphthyl, pyridyl, chinolyl, pyrazinyl, pyrimidyl, lyl, triazinyl, imidazolyl, furanyl, thienyl can be contained in the end product, wherein each hydrogen atom in each of the above-mentioned group independently of each other can be ed by a residue R1, as defined above in connection with the formula I. Such a method is also the contemplated herein.

The reaction shown in Fig. 2 is effected in inert, polar organic solvents. Inert polar organic solvents are, for example, ether such as diethylether, methyl-tert.-butylether, 1,2-dimethoxyethane, glycol diethyl ether or diethylene glycol dimethyl ether, cyclic ether, such as dioxane, tetrahydrofuran , hydrocarbons, such as ethyl e, xylene, toluene or alcohols, such as ethanol, propanol , butanol, isobutanol and isopropanol. Particularly pure products are obtained by using nbutanol as a solvent. nol should be used in a molar ratio of 1 to 10 , in ular preferably 1.5 to 3, in relation to the initial value of the pyrazole derivative.

Within the scope of the present disclosure it emerged as particularly useful if the idine (6) is freshly prepared in basic form (as free base). The synthesis is effected using the usual s from the correspondingly available salt. It is best to use benzamidine (6) in a molar ratio of 1 to 1.5, based on the pyrazole derivatives (5).

The reaction is d out at a temperature from 60 to 110°C, preferably 85 to 95°C, over 10-30 hours, preferably 18-20 hours.

The amino(phenylamino)phenylpyrazolo[3,4-d]pyrimidine (1) obtained in this way is cleaned by recrystallization. For this preferably tetrahydrofuran or a mixture of tetrahydrofuran with water or an c solvent is used, in particular preferably with toluene. Alternatively to that the amino- 3-(phenylamino)phenylpyrazolo[3,4-d]pyrimidine can also be cleaned by precipitation from a hot solution in tetrahydrofuran with water or an organic solvent, preferably with toluene.

In the following es special nds of the general formula (I) are listed, which are suitable preferably for applications against avirus infections, wherein the compounds can be prepared in a solution or a sion in a pharmaceutically acceptable aqueous, organic or aqueous-organic medium for the local or parenteral application by intravenous, subcutaneous or uscular injection or for intranasal administration, or ped in the form of a tablet, capsule or aqueous suspension with a conventional carrier for oral administration or as a suppository.

The compounds presented in the formula (I) can thus be used in doses of 0.1 to 1000 mg/kg body weight.

Manufacture and analysis of the 4-aminophenylaminophenylpyrazolo[3,4- d]pyrimidine derivatives The structural clarification of the compounds of the invention is ed by the type of synthesis, elementary analyses, NMR spectroscopy and mass spectrometery.

Source materials: The 5-aminocyanophenylaminopyrazoles were synthesised according to the method shown in Fig. 1 as well as according to the description of Tominaga Y et al. (J. Heterocycl. Chem., 1990, 27, 775-779). Arylamidines are synthesised according to the known prior art from the ponding cyanogen source compounds (Boere, RT et al.: J. Organomet. Chem., 1987, 331, 161-167; pati RS: Tetrahedron Lett., 1990, 31, 1969-1978; Dann O et al.: Justus Liebigs Ann. Chem., 1982, 1836-1839).

Reference e 1: 4-aminophenylaminophenylpyrazolo [3,4-d] pyrimidine (3-N,6-diphenyl-2H-pyrazolo[3,4-d]pyrimidine-3,4-diamine) 3.0 g (17.24 mmol) benzamidin hydrochloride hydrate and 2.2 g (23.0 mmol) sodium acetate are added to 2.3 g (11.5 mmol) 5-aminocyanophenylaminopyrazol whilst stirring. The reaction mixture is heated for 30 min at 220 °C. The resulting material is treated with 50 ml water, filtered and washed with 20 ml cold ol and 20 ml cold ester. The product is cleaned by means of crystallisation from DMF/water.

NH NH2 N N Ref-1 Light yellow, solid crystalline material. Yield 57 %. mp 253-5 °C. Rf(chloroform - methanol; 10/1) - 0.8 (silica gel 60). MS m/z 302 (M+).

Reference example 2: 4-amino(phenylamino)phenylpyrazolo[3,4-d]pyrimidine (alternative manufacture) .22 g benzamidine hydrochloride, previously dried for 2.5 hr at 115°C, is slowly added to a solution of 1.74 g sodium methylate in 100 ml methanol and stirred for 30 min at room temperature.

After filtering out the anorganic white precipitation 3.5 ml n-butanol is added and the volume reduced in the vacuum to 3 ml. The e is a whitish oil, and corresponds to 4.0 g benzamidine , which is used ately in the next reaction step. -aminocyano(phenylamino)-pyrazol (6.0 g; powder Ref-1) is dissolved in 10 ml n-butanol and 4.0 g benzamidine in 3 ml nol added at room temperature. The reaction takes place over 20 hours at 85°C. Finally, the solution is , the yellow precipitation filtered out and washed with 5 ml n-butanol and 5 ml toluene.

Yield: 68% Properties: Melting point: 265-267°C (tetrahydrofuran); MS (m/z) 302 (M+); 1H NMR (DMSO-d6): δ 12.38 (1H, s, NH), 8.30-8.36 (2H, q, 2 CH), 8,23 (1H, br. s., NH), 7.67 (2H, d, 2CH), 7.48 (2H, br. s., NH2), 7.42 (3H, m, 3CH), 7.12 (2H, d, 2CH) and 6.98 (1H, m, CH) ppm; Elementary analysis C17H14N6: Calculated %: C, 67.54; H, 4.67; N, 27.80; Found %: C, 67.49; H, 4.53; N, 27.74.

Reference example 3: o(4-chlorphenyl)aminophenylpyrazolo[3,4-d]pyrimidine (3-N-(4-chlorphenyl)phenyl-2H-pyrazolo[3,4-d]pyrimidine-3,4-diamine) NH NH2 N N Ref-3 Reference example 4: 4-amino(3,4-difluorphenyl)aminophenylpyrazolo[3,4- d]pyrimidine 3,4-difluorphenyl)phenyl-2H-pyrazolo[3,4-d]pyrimidine-3,4-diamine) NH NH2 F N N N Ref-4 Reference example 5: 4-amino[(4-fluorophenyl)amino]phenylpyrazolo[3,4- d]pyrimidine Ref-5 The compound Ref-5 is manufactured in the same way as shown in reference example 2, wherein however 5-aminocyano[(4-fluorophenyl)amino)-pyrazol was used as source material, thereby forming a light yellow crystalline precipitation.

Yield: 70% Properties: Melting point: 262-263°C (THF/toluene); MS (m/z): 320 (M'); 1H NMR d 6): δ 12.69 (1H, s, NH), .41 (4H, m, 4CH), 8.18 (1H, br. s., NH), 7.58-7.65 (5H, m, NH2, 3CH), 7.27-7.31 (2H, n, 2CH) ppm; Elementary analysis C17H14FN6: Calculated %: C, 63.74; H, 4.09; N, 26.24; Found %: C, 63.81; H, 4.11; N, 26.27.

Reference example 6: 4-amino[(3-fluorophenyl)amino]phenylpyrazolo[3,4- d]pyrimidine Ref-6 The compound Ref-6 is manufactured in the same way as ed in reference example 2,wherein however 5-aminocyano[(3-fluorophenyl)amino]-pyrazol was used as source components , thereby forming a light yellow crystalline precipitation.

Yield: 76% Properties: Melting point: 9°C (THF/toluene); MS (m/z): 320 (M+); 1H NMR (DMSO-d6); δ 12.61 (1H, s, NH), 8.34-8.42 (2H, q, 2CH), 8.14 (1H, br. s., NH), 7.48 (2H, br. s., NH2), 7.3-7.43 (6H, m, 6CH), 6.60 (1H, s, CH) ppm; Elementary analysis for C17H14FN6: Calculated %: C, 63.74; H, 4.09; N, 26.24; Found %: C, 63.81; H, 4.11; N, 26.27.

Example 1: 4-amino(4-trifluormethyl-phenyl)aminophenylpyrazolo[3,4-d]pyrimidine (CRCV-340) nylN-[4-(trifluormethyl)phenyl]-2H-pyrazolo[3,4-d]pyrimidine-3,4-diamine) The manufacture was effected as described in reference example 1, using the corresponding substituted precursor compounds.

NH NH2 N N CRCV-340 Example 2: 4-aminophenyl[(4-(trifluoromethyl)-phenyl]amino-pyrazolo[3,4- d]pyrimidine The compound. CRCV-340 was also ctured analogously to the reaction schedule shown in reference example 2, thereby forming a light yellow crystalline precipitation.

Yield: 58% ties: Melting point: 313-314°C (THF/Toluene); MS (m/z): 370 (M+); 1H NMR (DMSO-d6): δ 12.77 (1H, s, NH), 8.91 (1H, s, NH), 8.47 (2H, s, NH2), 7.81, 7.79, 7.63, 7.58 and 7.47 (9H, m, C6H4 and C6H5) ppm; Elementary analysis C18H13F3N6: Calculated %: C, 58.38; H, 3.54; N, 22,69; Found %: C, 58.41; H, 3.58; N, 22.74; HPLC: 99.30% (Säule Luna C18 (2), itrile /water - 90:10, flow of 0.6 ml/min, UV 254 nm; tR = 5.3 min) Example 3: ophenylamino[4-(trifluormethoxy)-phenyl]pyrazolo[3,4- d]pyrimidine (MS-112) (3-N-phenyl[4-(trifluormethoxy)phenyl]-2H-pyrazolo[3,4-d]pyrimidine-3,4-diamine) The manufacture was effected as described in reference example 1 using the correspondingly substituted precursor compounds.

NH NH2 N N F F F MS-112 Example 4: 4-aminophenyl[(4-(trifluoromethoxy)-phenylamino]-pyrazolo[3,4- d]pyrimidine This compound was also manufactured analogously to the reaction schedule shown in reference example 2, wherein 5-aminocyano[(4-trifluormethoxyphenyl)amino]pyrazol from source compound was used, y forming a white crystalline itation.

Yield: 68% Properties: Melting point: 260-262°C (tetrahydrofuran/DMF); MS (m/z): 386 (M'); 1H NMR (DMSO-d6): δ 12.56 (1H, s, NH), 8.82 (2H, q, 2CH), 8.16 (1H, br. s., NH), 7.48 (2H, br. s., NH2), 7.3-7.43 (4H, m, C6H5), 7.05-7.11 (2H, 2 s, 2CH), 6.98 (1H, m, CH) ppm; Elementary analysis C18H13F3N6O: Calculated %: C, 55.96; H, 3.39; N, 21.75; Found %: C, 56.07; H, 3.36; N, 21.61.

Example 5: Cleaning of 4-aminophenyl[(4-(trifluoromethyl)-phenyl]aminopyrazolo [3,4-d]pyrimidine 50g of dry 4-aminophenyl[(4-trifluoromethyl)-phenyl]amino-pyrazolo[3,4-d]pyrimidine, synthesised according to the method described in the reference example 2, is dissolved whilst being warmed in 300 ml of THF. This solution is treated with 300 ml cold toluene. The resulting solution is kept in a r at a temperature below 0°C for a period of 6 hours. 36 g of 4-amino(4- trifluorophenyl)aminophenylpyrazolo[3,4-d]pyrimidine in yellow crystals are ed by filtration.

Melting point: 313-314°C (THF/DMF) HPLC: 99.16% (Säule Luna C18(2), Acetonitrile/water -90:10, flow of 0.6 ml/min, UV 254 nm; tR = .3 min) ADMET studies on the metabolism of OBR 5-340 in vitro Objective: To investigate the Absorption, Distribution, Metabolism, Excretion and Toxicity (abbreviated as: ADMET) of OBR 5-340 in vitro, as well as In vitro tests on the plasma n binding and the stability in the plasma and in liver microsomes.

Tests: The In vitro tests performed with CRCV-340 as well as the data obtained are summarised in Table 2 in comparison with Ref. 2.

Table 2: Summary of the results from the ADMET studies for 40 in comparison with Ref Test parameters Ref-2 CRCV-340 Binding to plasma protein 99.5 % 96.7 % Release of plasma protein 61.0 % 122.3 % Plasma stability 117.0 % 100.0 % Stability in liver microsomes 32.0 % 112.0 % Summary: The nce 40 is characterised by better stability in liver microsomes as well as an sed release of plasma protein in comparison with Ref-2.

Examination of the pharmacokinetics of CRCV-340 in mice Objective: To collect pharmacokinetic data on CRCV-340.

Tests: nce and reference substance were applied respectively once in a concentration of 100 mg/kg KG, in 0.5 ml of a 10% Cremophor solution per os to the mice. After 0.5, 1, 2, 3, 4, 5, 6 and 7 hrs serum was taken and by means of HPLC analysis the concentrations of 40, Ref-2 and Ref-3 determined in the plasma of the mice.

Using the substance concentrations in the blood plasma determined by HPLC the pharmacokinetic parameters of the substances were calculated using the computer program ESTRIP (Table 3).

Table 3: Pharmacokinetic data following a single, intragastric application of 100 mg/kg CRCV- 340, Ref-2 and Ref-3 in mice.

Sub- C T MRT T K CL V AUC AUC C /A max max 1/2 el d 0-t 0-∞ max stance UC (ng/ml) (h) (h) (h) -1 -1 (h ) (ml× (ml/k (ng×ml (ng×ml/ (h ) h/kg) g) /h) h) Ref-2 1295.4 1.0 2.14 2.96 0.23 36.6 156.7 2354.5 2732.1 0.55 Ref-3 424.5 0.5 2.44 1.47 0.55 91.8 168.1 1085.7 1089.4 0.39 CRCV- 1254.4 3.0 3.54 3.54 0.18 10.4 52.7 6418.3 9598.5 0.20 Cmax Maximum concentration in the blood Tmax Time to reach the m concentration in the blood MRT Mean residence time T1/2 Half life Kel Elimination rate constant CL Clearance Vd Volume of distribution AUC Area under curve Cmax/AUC Absorption rate from h to blood Result: The tests on the pharmacokinetics in mice for 40 gave a significantly better bioavailability than for Ref-2 and Ref-3.

Tests on acute toxicity of CRCV-340 in mice Objective: To determine 50 % lethal dose of CRCV-340 Tests: The acute toxicity of the substance CRCV-340 was tested in mice 19.5 - 20.5 g in weight, which was administered per os 40, 60, 80 or 120 mg substance/mouse (per 5 mice per substance and concentration). This corresponds to a dose of approx. 2g, 3g, 4g or 6g per kilogramme body weight. The toxic effects observed in the result correlated to the substance dose administered. In the 40 and 60 mg/mouse doses up to 3 hrs after the nce was administered coordination disorders and hyperactivity were observed as side effects. Following stration of the two higher doses there were also ing difficulties, aggressive behaviour and hyperkinesia. For CRCV-340 a LD50 of 3120 mg/kg was determined (Table 4).

Table 4: s of the tests on acute toxicity of the substance CRCV-340 after a single peroral administration in mice Dose Dead/Surviving 72 hrs after administration of Ref-2 CRCV-340 40 mg/mouse 0/5 1/5 60 mg/mouse 1/5 1/5 80 mg/mouse 3/5 3/5 120 mg/mouse 4/5 5/5 LD50 78.6 mg/mouse (3930 mg/kg) 62.4 mg/mouse (3120 mg/kg) Result: The data obtained on the survival rate prove very good tolerance of both test substances.

Long term s on the toxicity in mice Objective: To determine the te toxicity in mice in order to reveal possible side effects e.g. on general condition, weight, internal organs and metabolism, which could arise with subacute administration of CRCV-340 over 28 days.

Tests: Thus male and female mice weighing approx. 20 g received 12.5, 50 or 200 mg/kg of the substance CRCV-340 in a Cremophor ation or the l group received Cremophor once a day over 28 days intragastrically administered via a tube. During the total period of the experiment the condition of the coat and the mucous membranes, the excreta and the general condition were assessed. The recording of the weight took place on days 7, 14, 21 and 28. Approx. 24 hrs. after the last substance dose the sense of direction of the animals was examined. The following mical parameters in the serum were analysed: n content, urea, creatinine, the serum activity of aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase. The haemoglobin concentration, hematocrit, the number of red and white blood cells as well as the platelets was determined in the blood smear. At the end of the experiment the mice were killed under anaesthetic and dissected, the condition of the internal organs were assessed macroscopically , the organ weight determined and samples for subsequent histological tests put into formalin.

Results summary: The results prove extremely good nce of the substance concentrations ed. Neither the general condition of the animals, their coats, the excreta nor their sene of ion or mobility changed as a result of the substance given. Also in relation to the body weight dynamic the animals treated with CRCV-340 did not differ from the control group. There were no differences between the test groups treated with the substance and the vehicle-treated groups in the blood smear in terms of the biochemical blood parameters. The same applies to the copic assessment of the internal organs (liver, kidney, heart, lung, spleen, pancreas and testes), the weight of the organs as well as the results of the histology tests of the heart, lung, liver, spleen, thymus, pancreas, kidney, gland, testes, stomach and intestinal tissue samples (results not shown).

Determining the antiviral um against rhinoviruses Objective: To ine the antiviral effective spectrum of CRCV-340 in respect of 50 different human rhinovirus serotypes and CVB3 patient isolates.

Tests: The 50 HRV serotypes and 20 clinical CVB3 es were reproduced in HeLa, HeLa Wis and/or LF cells, their titre determined and the serotype verified using sequencing. Accordingly zpE (zytopathic effect) inhibitory tests with the HRV or plaque-reductions tests with the CVB3 isolates were ished. In the corresponding antiviral tests dose effect investigations with Ref- 3 and CRCV-340 were carried out. Tables 5 and 6 give an overview of the mean 50 % inhibitory concentrations.

Table 5: Overview of the effective spectrum of Ref-3 and CRCV-340 in respect of HRV. The mean values and standard ions for all 50 examined serotypes and for the 45 pleconarilsensitive and 5 aril-resistant serotypes were ised separately.

Substance IC [μM] IC [μM] Plecon- IC [μM] Plecon- Number of 50 50 50 all HRV aril-sensitive esistant HRV sensitive (n = 50) HRV (n = 5) HRV (n = 45) mean S. D. mean S. D mean S. D.

Ref-3 16.11 11.94 18.52 10.88 0.07 0.01 23 CRCV-340 25.73 21.49 26.09 18.98 22.62 40.69 49 Table 6: Overview of the effective um of Ref-3 and CRCV-340 in respect of the al CVB3-isolates. The mean values and standard deviations for all 20 examined es and for the 19 pleconaril-sensitive es and the one pleconaril-resistant serotype were summarised separately.

Substance IC [μM] IC [μM] Plecon- IC [μM] Plecon- Number of 50 50 50 all CVB3 ensitive aril-resistant sensitive (n = 20) CVB3 CVB3 CVB3 (n = 19) (n = 1) mean S. D. mean S. D mean S. D.

Ref-3 0.68 0.90 0.71 0.91 0.13 20 CRCV-340 4.97 4.05 5.16 4.10 1.39 18* * maximum tested concentration 13.5 μM Result summary: The effective spectrum of CRCV-340 in respect of HRV was significantly broader in comparison to Ref-3.

Examination of the antiviral effect in vivo in the mouse model of CVB3-induced chronic myocarditis Objective: To confirm the antiviral effect of CRCV-340 in the mouse model Investigations: The effect of CRCV-340 was investigated in the model of CVB 3-induced ditis in 8-week old male NMRI mice. In addition CVB3 3193 or CVB3 H3-infected animals received once or twice a day 100 mg/kg of the substance in 50 % or 20 % PEG-400 in 1 % CMC in water (placebo) administered over 7 days. ters to evaluate the therapeutic effect ed changes in body weight, general condition, virus titre in heart and pancreas tissue as well as histopathological changes in the heart and pancreas. Pseudo-infected, placebo-treated or CRCV- eated animals served as a negative control and infected, placebo- or pleconaril-treated animals as a positive control over the course of the infection.

Result summary: In contrast to the placebo and pleconaril CRCV-340 was effective in the model of the CVB3 3193-induced chronic myocarditis in NMRI-mice. In the process clinically and tically significant effects for all examined parameters (body weight, general condition, the virus titre in the heart and pancreas tissue on day 7 p.i., the histopathology in the heart and pancreas on day 7 and 21 p.i.) were observed.

Studies on the in vivo effectiveness of CRCV-340 in the lethal mouse model compared to the reference nce pleconaril ive: To verify the antiviral effect of CRCV-340 in the lethal mouse model Investigations: The effect of the development candidate CRCV-340 was ed ing testing of the ion dose in the model of the CVB 3-induced myocarditis in 6 - 7 weeks old male BALB/c mice. In addition CVB3 3193 or CVB3 H3-infected animals received twice a day 100 mg/kg of the substance in 20 % PEG-400 in 1 % CMC in water (placebo) administered over 7 days. Changes in body weight, general condition and the ity defined through the surrogate marker 25 % loss of body weight served as parameters to evaluate the therapeutic effect. Pseudo-infected , placebo-treated or CRCVtreated animals represented the negative control and infected, placebo- or pleconaril-treated animals the positive control over the course of the infection.

Result summary: In contrast to the placebo and pleconaril CRCV-340 was effective in the lethal BALB/c mouse model after infection with CVB3 3193. In the process clinically and statistically significant effects for all examined parameters (body weight, l condition as well as lethality) were observed. The term ‘comprising’ as used in this specification and claims means ‘consisting at least in part of’. When reting statements in this specification and claims which includes the ‘comprising’, other features besides the features prefaced by this term in each statement can also be t. Related terms such as ‘comprise’ and ‘comprised’ are to be interpreted in similar In this specification where reference has been made to patent specifications, other external nts , or other sources of information, this is generally for the purpose of providing a context for discussing the features of the ion. Unless specifically stated otherwise, reference to such external documents is not to be construed as an admission that such documents, or such sources of information, in any jurisdiction, are prior art, or form part of the common general knowledge in the art.

Claims (22)

We claim:

1. 4-aminophenylaminophenylpyrazolo[3,4-d]pyrimidine derivatives of the general formula I NH NH2 N N H B or a pharmaceutically acceptable salt or pro-drug thereof, wherein the pro-drug has a imino(phenyl)methyl substituent on the pyrazol heteroatom in position 1, wherein at least one hydrogen atom in at least one of the phenyl groups A and B is substituted by a substituent RH which has a Hammett constant σp r than 0.23, wherein each further en atom in each of the phenyl groups A and B can be substituted independently of each other by a residue R1, wherein each R1 independently can be a halogen, a saturated or unsaturated, linear or branched aliphatic radical with 1-7 chain members, a saturated or unsaturated, linear or ed alcanol radical with 1-8 chain members, NO2, CN, CONR22, COR2, COOR2, OR2, SR2, NR22, SO2NR22, CX3, CR2X2, OCX3, OCR2X2, or phenyl each R2 independently is hydrogen, a saturated or unsaturated, halogenated or non-halogenated, linear or branched aliphatic radical with 1-7 chain members, benzyl, phenyl or naphtyl, a saturated or unsaturated, mono- or polyheterocycle with the heteroatoms N, S or O, wherein each of the groups mentioned above independently can be substituted with fluorine, chlorine, e, trifluormethyl, alkyl , alkoxy, cyano, nitro, amino, aminoalkyl, lkyl, alkyl, , phenyl or naphtyl; and X independently is F, Cl, Br, or I.

2. 4-aminophenylaminophenylpyrazolo[3,4-d]pyrimidine derivatives according to Claim 1, n at least one substituent RH independently is NO2, CN, CF3, CCl3, CBr3, OCF3, OCCl3, OCBr3, CHF2, CHCl2, CHBr2, OCHCl2, CHO, COOH, COMe, COEt, COOMe or COOEt, preferably CF3 or OCF3.

3. 4-aminophenylaminophenylpyrazolo[3,4-d]pyrimidine derivatives according to Claim 1 of the general formula II NH NH2 N N H B wherein each substituent RA, RB independently can be hydrogen, a halogen, a saturated or unsaturated, linear or branched aliphatic radical with 1-7 chain members, a saturated or rated, linear or branched alcanol radical with 1-8 chain members, NO2, CN, CONR22, COR2, COOR2, OR2, SR2, NR22, SO2NR22, CX3, CR2X2, OCX3, OCR2X2, or phenyl wherein R2 and X are d as in Claim 1; wherein at least one of the substituents RA, RB has a Hammett constant σp greater than 0.23.

4. ophenylaminophenylpyrazolo[3,4-d]pyrimidine derivatives according to Claim 1 or Claim 2 of the general formula IIa NH NH2 N N IIa, or IIb NH NH2 N N R IIb, wherein RH is NO2, CN, CF3, CCl3, CBr3, OCF3, OCCl3, OCBr3, CHF2, CHCl2, CHBr2, OCHCl2, CHO, COOH, COMe, COEt, COOMe or COOEt, preferably CF3 or OCF3.

5. 4-aminophenylaminophenylpyrazolo[3,4-d]pyrimidine derivatives according to Claim 4 of the a F NH NH2 N N NH NH2 N N F F F .

6. Pharmaceutical composition, comprising a 4-aminophenylaminophenylpyrazolo[3,4- d]pyrimidine derivative according to any one of the previous claims.

7. Pharmaceutical composition according to Claim 6, also comprising a ceutically acceptable carrier.

8. Pharmaceutical ition according to Claim 6 or Claim 7, also comprising one or several other active ingredients.

9. Pharmaceutical composition according to Claim 8, wherein the one or the several other active ingredients are antiviral .

10. Pharmaceutical ition according to claim 9, wherein the other active agents are against picornaviruses.

11. Method of cturing a pharmaceutical composition, comprising formulating a 4- aminophenylaminophenylpyrazolo[3,4-d]pyrimidine derivative according to any one of Claims 1-5 with a pharmaceutically acceptable carrier.

12. Use of a 4-aminophenylaminophenylpyrazolo[3,4-d]pyrimidine derivative according to any one of Claims 1-5 in the manufacture of a medicament.

13. Use of a 4-aminophenylaminophenylpyrazolo[3,4-d]pyrimidine derivative according to any one of Claims 1-5 in the manufacture of a medicament for the lactic or therapeutic treatment of a viral infection.

14. The use according to Claim 13, wherein the viral infection is a picornavirus infection.

15. Method of manufacturing a 4-aminophenylaminophenylpyrazolo[3,4-d]pyrimidine derivative according to any one of Claims 1 to 5 or according to the formula I in Claim 1, wherein each hydrogen atom in each of the phenyl groups A and B independently of each other can be tuted by a residue R1, as defined in Claim 1, comprising the conversion of a 5-aminocyanophenylaminopyrazol with the free base of a benzamidine in a polar organic solvent.

16. The method of Claim 15, wherein the polar organic solvent is n-butanol.

17. Method according to Claim 15, wherein the 4-aminophenylamino pyrazolo[3,4-d]pyrimidine derivative is ed by recrystallisation using tetrahydrofuran or a mixture thereof with water or an organic solvent or by precipitation using a hot solution in tetrahydrofuran with water or an organic solvent.

18. The method of Claim 17, n the organic solvent is toluene.

19. 4-aminophenylaminophenylpyrazolo[3,4-d]pyrimidine derivatives as claimed in any one of Claims 1 to 5, ntially as herein described with reference to any example thereof.

20. A pharmaceutical composition as claimed in any one of claims 6 to 10, substantially as herein described with reference to any example f.

21. A method as claimed in any one of claims 11, 15 to 18, ntially as herein described with reference to any example thereof.

22. A use as claimed in any one of claims 12 to 14, substantially as herein described with reference to any example thereof.